Tricida, Inc. announced that it will present at the H.C. Wainwright 24th Annual Global Investment Conference. Tricida will provide a company overview, business update and progress on the company’s key initiatives.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the H.C. Wainwright 24th Annual Global Investment Conference. Tricida will provide a company overview, business update and progress on the company’s key initiatives.
The presentation will be accessible on the Tricida website at IR.Tricida.com on Monday, September 12, 2022 at 4:30 pm PT / 1:30 pm ET. An archive of the presentation will be available for 90 days following the presentation.
About Tricida
Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to slow CKD progression in patients with metabolic acidosis and CKD. Tricida is currently conducting a renal outcomes clinical trial, VALOR-CKD, to determine if veverimer slows CKD progression in patients with metabolic acidosis associated with CKD. Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. It is estimated to pose a health risk to approximately 4.3 million patients with CKD in the United States. There are currently no therapies approved by the FDA to slow progression of kidney disease by correcting chronic metabolic acidosis in patients with CKD.
For more information about Tricida, please visit Tricida.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220906005225/en/
Contacts
Jackie Cossmon
Tricida, Inc.
Senior Vice President of Investor Relations and Communications
IR@Tricida.com
Source: Tricida, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20220906005225/en
